Sustained Amisulpride Response in Postoperative Nausea & Vomiting: Phase III Data at ASPAN 2024

Eagle Pharmaceuticals, Inc. has recently shared promising results from a Phase III clinical trial involving amisulpride, a medication used for the rescue treatment of postoperative nausea and vomiting (PONV). The trial was a randomized, multicenter, double-blind, and placebo-controlled study that focused on adult surgical patients who were at moderate to high risk of PONV and had not responded to initial antiemetic treatments.

The pharmacokinetic data from a subset of these patients indicated that a single 10 mg intravenous dose of amisulpride could maintain therapeutic plasma levels for up to 24 hours. This finding suggests that amisulpride has the potential to provide a sustained antiemetic effect, which is particularly beneficial for patients who have already failed prophylactic antiemetic therapy.

Mike Greenberg, MD, the Vice President of Medical Affairs at Eagle Pharmaceuticals, highlighted the significance of these results. He expressed confidence that the sustained response delivered by a single dose of amisulpride could be instrumental in the rescue setting, potentially leading to broader recognition of its utility by healthcare providers. This, in turn, could bolster confidence in post-surgical and discharge outcomes.

The detailed findings were presented in a poster at the ASPAN 2024 National Conference, which took place in Orlando, Florida. The poster, titled "Documented Sustained Response of Intravenous Amisulpride for Rescue Treatment of Postoperative Nausea and Vomiting: Results from a Phase III Trial," was presented by Dr. Lynn Bichajian.

Eagle Pharmaceuticals is a comprehensive pharmaceutical company with a strong focus on research and development, clinical expertise, manufacturing, and commercialization. The company is dedicated to creating innovative medicines that can significantly improve patients' lives. Its product portfolio includes a range of commercialized products, and it has a robust pipeline targeting oncology and CNS/metabolic critical care areas, with an aim to develop personalized medicine approaches in postoperative care.

The study's results are a testament to Eagle Pharmaceuticals' commitment to advancing patient care through scientific research and development. The potential application of amisulpride in PONV rescue treatment could represent a significant step forward in postoperative care, offering a new option for patients who have not found relief through standard antiemetic prophylaxis.